Daxor Corporation
Daxor Corporation (DXR) Stock Competitors & Peer Comparison
See (DXR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXR | $10.25 | +4.91% | 51.7M | 6.26 | $1.64 | N/A |
| ISRG | $482.22 | +0.71% | 170.8B | 58.52 | $8.24 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.45% |
| BDX | $152.14 | -1.75% | 55.1B | 24.86 | $6.12 | +2.45% |
| ALC | $75.80 | -0.08% | 36.9B | 38.28 | $1.98 | +0.44% |
| MDLN | $44.76 | -3.18% | 36.3B | 31.30 | $1.43 | N/A |
| RMD | $219.85 | +0.15% | 32.1B | 21.74 | $10.11 | +1.06% |
| WST | $306.16 | -1.14% | 22.1B | 40.87 | $7.49 | +0.28% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.45% |
Stock Comparison
DXR vs ISRG Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, ISRG has a market cap of 170.8B. Regarding current trading prices, DXR is priced at $10.25, while ISRG trades at $482.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas ISRG's P/E ratio is 58.52. In terms of profitability, DXR's ROE is +0.22%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, DXR is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ISRG's competition here
DXR vs BDXA Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, DXR is priced at $10.25, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas BDXA's P/E ratio is 21.44. In terms of profitability, DXR's ROE is +0.22%, compared to BDXA's ROE of +0.07%. Regarding short-term risk, DXR is more volatile compared to BDXA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BDXA's competition here
DXR vs BDX Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, BDX has a market cap of 55.1B. Regarding current trading prices, DXR is priced at $10.25, while BDX trades at $152.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas BDX's P/E ratio is 24.86. In terms of profitability, DXR's ROE is +0.22%, compared to BDX's ROE of +0.07%. Regarding short-term risk, DXR is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BDX's competition here
DXR vs ALC Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, ALC has a market cap of 36.9B. Regarding current trading prices, DXR is priced at $10.25, while ALC trades at $75.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas ALC's P/E ratio is 38.28. In terms of profitability, DXR's ROE is +0.22%, compared to ALC's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ALC's competition here
DXR vs MDLN Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, MDLN has a market cap of 36.3B. Regarding current trading prices, DXR is priced at $10.25, while MDLN trades at $44.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas MDLN's P/E ratio is 31.30. In terms of profitability, DXR's ROE is +0.22%, compared to MDLN's ROE of +0.08%. Regarding short-term risk, DXR is more volatile compared to MDLN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check MDLN's competition here
DXR vs RMD Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, RMD has a market cap of 32.1B. Regarding current trading prices, DXR is priced at $10.25, while RMD trades at $219.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas RMD's P/E ratio is 21.74. In terms of profitability, DXR's ROE is +0.22%, compared to RMD's ROE of +0.25%. Regarding short-term risk, DXR is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check RMD's competition here
DXR vs WST Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, WST has a market cap of 22.1B. Regarding current trading prices, DXR is priced at $10.25, while WST trades at $306.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas WST's P/E ratio is 40.87. In terms of profitability, DXR's ROE is +0.22%, compared to WST's ROE of +0.18%. Regarding short-term risk, DXR is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check WST's competition here
DXR vs HOLX Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, DXR is priced at $10.25, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas HOLX's P/E ratio is 31.54. In terms of profitability, DXR's ROE is +0.22%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, DXR is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check HOLX's competition here
DXR vs BDXB Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, DXR is priced at $10.25, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas BDXB's P/E ratio is 7.60. In terms of profitability, DXR's ROE is +0.22%, compared to BDXB's ROE of +0.07%. Regarding short-term risk, DXR is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BDXB's competition here
DXR vs COO Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, COO has a market cap of 12.6B. Regarding current trading prices, DXR is priced at $10.25, while COO trades at $64.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas COO's P/E ratio is 33.21. In terms of profitability, DXR's ROE is +0.22%, compared to COO's ROE of +0.05%. Regarding short-term risk, DXR is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check COO's competition here
DXR vs BAX Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, BAX has a market cap of 9.4B. Regarding current trading prices, DXR is priced at $10.25, while BAX trades at $18.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas BAX's P/E ratio is -10.56. In terms of profitability, DXR's ROE is +0.22%, compared to BAX's ROE of -0.14%. Regarding short-term risk, DXR is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BAX's competition here
DXR vs MASI Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, DXR is priced at $10.25, while MASI trades at $178.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas MASI's P/E ratio is 46.52. In terms of profitability, DXR's ROE is +0.22%, compared to MASI's ROE of -0.17%. Regarding short-term risk, DXR is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check MASI's competition here
DXR vs ATR Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, ATR has a market cap of 8B. Regarding current trading prices, DXR is priced at $10.25, while ATR trades at $124.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas ATR's P/E ratio is 21.06. In terms of profitability, DXR's ROE is +0.22%, compared to ATR's ROE of +0.15%. Regarding short-term risk, DXR is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ATR's competition here
DXR vs RGEN Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, RGEN has a market cap of 6.6B. Regarding current trading prices, DXR is priced at $10.25, while RGEN trades at $117.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas RGEN's P/E ratio is 135.17. In terms of profitability, DXR's ROE is +0.22%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, DXR is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check RGEN's competition here
DXR vs TFX Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, TFX has a market cap of 6B. Regarding current trading prices, DXR is priced at $10.25, while TFX trades at $136.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas TFX's P/E ratio is 103.45. In terms of profitability, DXR's ROE is +0.22%, compared to TFX's ROE of -0.24%. Regarding short-term risk, DXR is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check TFX's competition here
DXR vs BLCO Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, BLCO has a market cap of 5.6B. Regarding current trading prices, DXR is priced at $10.25, while BLCO trades at $15.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas BLCO's P/E ratio is -15.49. In terms of profitability, DXR's ROE is +0.22%, compared to BLCO's ROE of -0.06%. Regarding short-term risk, DXR is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BLCO's competition here
DXR vs AVTR Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, AVTR has a market cap of 5.4B. Regarding current trading prices, DXR is priced at $10.25, while AVTR trades at $7.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas AVTR's P/E ratio is -10.13. In terms of profitability, DXR's ROE is +0.22%, compared to AVTR's ROE of -0.09%. Regarding short-term risk, DXR is more volatile compared to AVTR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check AVTR's competition here
DXR vs STVN Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, STVN has a market cap of 4.4B. Regarding current trading prices, DXR is priced at $10.25, while STVN trades at $16.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas STVN's P/E ratio is 27.02. In terms of profitability, DXR's ROE is +0.22%, compared to STVN's ROE of +0.10%. Regarding short-term risk, DXR is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check STVN's competition here
DXR vs MMSI Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, MMSI has a market cap of 4.1B. Regarding current trading prices, DXR is priced at $10.25, while MMSI trades at $68.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas MMSI's P/E ratio is 32.20. In terms of profitability, DXR's ROE is +0.22%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, DXR is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check MMSI's competition here
DXR vs ICUI Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, ICUI has a market cap of 3.1B. Regarding current trading prices, DXR is priced at $10.25, while ICUI trades at $124.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas ICUI's P/E ratio is 4160.67. In terms of profitability, DXR's ROE is +0.22%, compared to ICUI's ROE of +0.00%. Regarding short-term risk, DXR is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ICUI's competition here
DXR vs HAE Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, HAE has a market cap of 2.8B. Regarding current trading prices, DXR is priced at $10.25, while HAE trades at $59.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas HAE's P/E ratio is 16.52. In terms of profitability, DXR's ROE is +0.22%, compared to HAE's ROE of +0.20%. Regarding short-term risk, DXR is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check HAE's competition here
DXR vs WRBY Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, WRBY has a market cap of 2.8B. Regarding current trading prices, DXR is priced at $10.25, while WRBY trades at $22.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas WRBY's P/E ratio is 2284.00. In terms of profitability, DXR's ROE is +0.22%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, DXR is more volatile compared to WRBY. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check WRBY's competition here
DXR vs LMAT Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, LMAT has a market cap of 2.6B. Regarding current trading prices, DXR is priced at $10.25, while LMAT trades at $113.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas LMAT's P/E ratio is 45.02. In terms of profitability, DXR's ROE is +0.22%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, DXR is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check LMAT's competition here
DXR vs XRAY Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, XRAY has a market cap of 2.4B. Regarding current trading prices, DXR is priced at $10.25, while XRAY trades at $11.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas XRAY's P/E ratio is -3.97. In terms of profitability, DXR's ROE is +0.22%, compared to XRAY's ROE of -0.35%. Regarding short-term risk, DXR is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check XRAY's competition here
DXR vs PLSE Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, PLSE has a market cap of 1.6B. Regarding current trading prices, DXR is priced at $10.25, while PLSE trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas PLSE's P/E ratio is -21.31. In terms of profitability, DXR's ROE is +0.22%, compared to PLSE's ROE of -0.73%. Regarding short-term risk, DXR is more volatile compared to PLSE. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check PLSE's competition here
DXR vs ATRC Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, ATRC has a market cap of 1.5B. Regarding current trading prices, DXR is priced at $10.25, while ATRC trades at $29.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas ATRC's P/E ratio is -122.00. In terms of profitability, DXR's ROE is +0.22%, compared to ATRC's ROE of -0.02%. Regarding short-term risk, DXR is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ATRC's competition here
DXR vs NVCR Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, NVCR has a market cap of 1.4B. Regarding current trading prices, DXR is priced at $10.25, while NVCR trades at $12.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas NVCR's P/E ratio is -10.22. In terms of profitability, DXR's ROE is +0.22%, compared to NVCR's ROE of -0.39%. Regarding short-term risk, DXR is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check NVCR's competition here
DXR vs KMTS Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, KMTS has a market cap of 1.3B. Regarding current trading prices, DXR is priced at $10.25, while KMTS trades at $22.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas KMTS's P/E ratio is -4.11. In terms of profitability, DXR's ROE is +0.22%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, DXR is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check KMTS's competition here
DXR vs STAA Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, STAA has a market cap of 1.3B. Regarding current trading prices, DXR is priced at $10.25, while STAA trades at $25.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas STAA's P/E ratio is -15.85. In terms of profitability, DXR's ROE is +0.22%, compared to STAA's ROE of -0.23%. Regarding short-term risk, DXR is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check STAA's competition here
DXR vs NNNN Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, NNNN has a market cap of 1.2B. Regarding current trading prices, DXR is priced at $10.25, while NNNN trades at $27.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas NNNN's P/E ratio is 182.33. In terms of profitability, DXR's ROE is +0.22%, compared to NNNN's ROE of +0.23%. Regarding short-term risk, DXR is more volatile compared to NNNN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check NNNN's competition here
DXR vs AZTA Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, AZTA has a market cap of 1.2B. Regarding current trading prices, DXR is priced at $10.25, while AZTA trades at $25.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas AZTA's P/E ratio is 44.67. In terms of profitability, DXR's ROE is +0.22%, compared to AZTA's ROE of -0.03%. Regarding short-term risk, DXR is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check AZTA's competition here
DXR vs BLFS Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, BLFS has a market cap of 1B. Regarding current trading prices, DXR is priced at $10.25, while BLFS trades at $21.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas BLFS's P/E ratio is -85.52. In terms of profitability, DXR's ROE is +0.22%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, DXR is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BLFS's competition here
DXR vs ATRI Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, DXR is priced at $10.25, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas ATRI's P/E ratio is 64.50. In terms of profitability, DXR's ROE is +0.22%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, DXR is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ATRI's competition here
DXR vs QDEL Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, QDEL has a market cap of 789.1M. Regarding current trading prices, DXR is priced at $10.25, while QDEL trades at $11.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas QDEL's P/E ratio is -0.69. In terms of profitability, DXR's ROE is +0.22%, compared to QDEL's ROE of -0.46%. Regarding short-term risk, DXR is more volatile compared to QDEL. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check QDEL's competition here
DXR vs ANGO Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, ANGO has a market cap of 458.6M. Regarding current trading prices, DXR is priced at $10.25, while ANGO trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas ANGO's P/E ratio is -14.61. In terms of profitability, DXR's ROE is +0.22%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, DXR is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ANGO's competition here
DXR vs UTMD Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, UTMD has a market cap of 215.2M. Regarding current trading prices, DXR is priced at $10.25, while UTMD trades at $67.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas UTMD's P/E ratio is 19.30. In terms of profitability, DXR's ROE is +0.22%, compared to UTMD's ROE of +0.10%. Regarding short-term risk, DXR is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check UTMD's competition here
DXR vs INFU Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, INFU has a market cap of 208.8M. Regarding current trading prices, DXR is priced at $10.25, while INFU trades at $10.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas INFU's P/E ratio is 32.28. In terms of profitability, DXR's ROE is +0.22%, compared to INFU's ROE of +0.12%. Regarding short-term risk, DXR is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check INFU's competition here
DXR vs OSUR Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, OSUR has a market cap of 207.4M. Regarding current trading prices, DXR is priced at $10.25, while OSUR trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas OSUR's P/E ratio is -3.19. In terms of profitability, DXR's ROE is +0.22%, compared to OSUR's ROE of -0.19%. Regarding short-term risk, DXR is more volatile compared to OSUR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check OSUR's competition here
DXR vs STXS Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, STXS has a market cap of 187.7M. Regarding current trading prices, DXR is priced at $10.25, while STXS trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas STXS's P/E ratio is -7.72. In terms of profitability, DXR's ROE is +0.22%, compared to STXS's ROE of -1.92%. Regarding short-term risk, DXR is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check STXS's competition here
DXR vs KRMD Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, KRMD has a market cap of 183.6M. Regarding current trading prices, DXR is priced at $10.25, while KRMD trades at $3.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas KRMD's P/E ratio is -66.00. In terms of profitability, DXR's ROE is +0.22%, compared to KRMD's ROE of -0.16%. Regarding short-term risk, DXR is more volatile compared to KRMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check KRMD's competition here
DXR vs SMTI Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, SMTI has a market cap of 176.2M. Regarding current trading prices, DXR is priced at $10.25, while SMTI trades at $19.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas SMTI's P/E ratio is -384.40. In terms of profitability, DXR's ROE is +0.22%, compared to SMTI's ROE of -1.79%. Regarding short-term risk, DXR is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check SMTI's competition here
DXR vs PDEX Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, PDEX has a market cap of 167M. Regarding current trading prices, DXR is priced at $10.25, while PDEX trades at $52.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas PDEX's P/E ratio is 15.28. In terms of profitability, DXR's ROE is +0.22%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, DXR is more volatile compared to PDEX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check PDEX's competition here
DXR vs NYXH Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, NYXH has a market cap of 111.3M. Regarding current trading prices, DXR is priced at $10.25, while NYXH trades at $2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas NYXH's P/E ratio is -1.07. In terms of profitability, DXR's ROE is +0.22%, compared to NYXH's ROE of -1.35%. Regarding short-term risk, DXR is more volatile compared to NYXH. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check NYXH's competition here
DXR vs MBOT Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, MBOT has a market cap of 100.3M. Regarding current trading prices, DXR is priced at $10.25, while MBOT trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas MBOT's P/E ratio is -7.59. In terms of profitability, DXR's ROE is +0.22%, compared to MBOT's ROE of -0.24%. Regarding short-term risk, DXR is more volatile compared to MBOT. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check MBOT's competition here
DXR vs AKYA Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, DXR is priced at $10.25, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas AKYA's P/E ratio is -1.34. In terms of profitability, DXR's ROE is +0.22%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, DXR is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check AKYA's competition here
DXR vs OMIC Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, DXR is priced at $10.25, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas OMIC's P/E ratio is -0.58. In terms of profitability, DXR's ROE is +0.22%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, DXR is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check OMIC's competition here
DXR vs ZTEK Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, ZTEK has a market cap of 50.6M. Regarding current trading prices, DXR is priced at $10.25, while ZTEK trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas ZTEK's P/E ratio is -7.84. In terms of profitability, DXR's ROE is +0.22%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, DXR is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ZTEK's competition here
DXR vs IGAP Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, DXR is priced at $10.25, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas IGAP's P/E ratio is -10.52. In terms of profitability, DXR's ROE is +0.22%, compared to IGAP's ROE of +0.00%. Regarding short-term risk, DXR is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check IGAP's competition here
DXR vs STSS Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, STSS has a market cap of 48M. Regarding current trading prices, DXR is priced at $10.25, while STSS trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas STSS's P/E ratio is -0.18. In terms of profitability, DXR's ROE is +0.22%, compared to STSS's ROE of -1.56%. Regarding short-term risk, DXR is more volatile compared to STSS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check STSS's competition here
DXR vs POCI Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, POCI has a market cap of 32.1M. Regarding current trading prices, DXR is priced at $10.25, while POCI trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas POCI's P/E ratio is -4.56. In terms of profitability, DXR's ROE is +0.22%, compared to POCI's ROE of -0.61%. Regarding short-term risk, DXR is more volatile compared to POCI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check POCI's competition here
DXR vs NEPH Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, NEPH has a market cap of 31M. Regarding current trading prices, DXR is priced at $10.25, while NEPH trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas NEPH's P/E ratio is 26.45. In terms of profitability, DXR's ROE is +0.22%, compared to NEPH's ROE of +0.12%. Regarding short-term risk, DXR is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NEPH's competition here
DXR vs HBIO Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, HBIO has a market cap of 30.7M. Regarding current trading prices, DXR is priced at $10.25, while HBIO trades at $6.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas HBIO's P/E ratio is -0.54. In terms of profitability, DXR's ROE is +0.22%, compared to HBIO's ROE of -3.89%. Regarding short-term risk, DXR is more volatile compared to HBIO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check HBIO's competition here
DXR vs SDC Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, DXR is priced at $10.25, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas SDC's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to SDC's ROE of -1.96%. Regarding short-term risk, DXR is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check SDC's competition here
DXR vs EKSO Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, EKSO has a market cap of 27.1M. Regarding current trading prices, DXR is priced at $10.25, while EKSO trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas EKSO's P/E ratio is -2.27. In terms of profitability, DXR's ROE is +0.22%, compared to EKSO's ROE of -1.11%. Regarding short-term risk, DXR is more volatile compared to EKSO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check EKSO's competition here
DXR vs MLSS Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, MLSS has a market cap of 25.9M. Regarding current trading prices, DXR is priced at $10.25, while MLSS trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas MLSS's P/E ratio is -4.59. In terms of profitability, DXR's ROE is +0.22%, compared to MLSS's ROE of -1.74%. Regarding short-term risk, DXR is more volatile compared to MLSS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check MLSS's competition here
DXR vs IVC Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, DXR is priced at $10.25, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas IVC's P/E ratio is -0.79. In terms of profitability, DXR's ROE is +0.22%, compared to IVC's ROE of -0.46%. Regarding short-term risk, DXR is more volatile compared to IVC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check IVC's competition here
DXR vs RVP Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, RVP has a market cap of 19.5M. Regarding current trading prices, DXR is priced at $10.25, while RVP trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas RVP's P/E ratio is -1.51. In terms of profitability, DXR's ROE is +0.22%, compared to RVP's ROE of -0.17%. Regarding short-term risk, DXR is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check RVP's competition here
DXR vs ZJYL Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, ZJYL has a market cap of 16.9M. Regarding current trading prices, DXR is priced at $10.25, while ZJYL trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas ZJYL's P/E ratio is 10.80. In terms of profitability, DXR's ROE is +0.22%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, DXR is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ZJYL's competition here
DXR vs RGNT Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, RGNT has a market cap of 12.2M. Regarding current trading prices, DXR is priced at $10.25, while RGNT trades at $3.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas RGNT's P/E ratio is -0.13. In terms of profitability, DXR's ROE is +0.22%, compared to RGNT's ROE of N/A. Regarding short-term risk, DXR is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check RGNT's competition here
DXR vs FEMY Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, FEMY has a market cap of 12M. Regarding current trading prices, DXR is priced at $10.25, while FEMY trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas FEMY's P/E ratio is -0.87. In terms of profitability, DXR's ROE is +0.22%, compared to FEMY's ROE of -5.35%. Regarding short-term risk, DXR is more volatile compared to FEMY. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check FEMY's competition here
DXR vs NXGL Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, NXGL has a market cap of 6.9M. Regarding current trading prices, DXR is priced at $10.25, while NXGL trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas NXGL's P/E ratio is -1.70. In terms of profitability, DXR's ROE is +0.22%, compared to NXGL's ROE of -0.61%. Regarding short-term risk, DXR is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NXGL's competition here
DXR vs NSTG Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, DXR is priced at $10.25, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas NSTG's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, DXR is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NSTG's competition here
DXR vs LUCY Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, LUCY has a market cap of 4.2M. Regarding current trading prices, DXR is priced at $10.25, while LUCY trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas LUCY's P/E ratio is -0.55. In terms of profitability, DXR's ROE is +0.22%, compared to LUCY's ROE of -0.00%. Regarding short-term risk, DXR is more volatile compared to LUCY. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check LUCY's competition here
DXR vs NXGLW Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, NXGLW has a market cap of 4M. Regarding current trading prices, DXR is priced at $10.25, while NXGLW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas NXGLW's P/E ratio is -0.04. In terms of profitability, DXR's ROE is +0.22%, compared to NXGLW's ROE of -0.61%. Regarding short-term risk, DXR is more volatile compared to NXGLW. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check NXGLW's competition here
DXR vs POAI Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, DXR is priced at $10.25, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas POAI's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to POAI's ROE of +29.59%. Regarding short-term risk, DXR is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check POAI's competition here
DXR vs MHUA Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, DXR is priced at $10.25, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas MHUA's P/E ratio is 0.25. In terms of profitability, DXR's ROE is +0.22%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, DXR is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check MHUA's competition here
DXR vs GMVD Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $10.25, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas GMVD's P/E ratio is -0.01. In terms of profitability, DXR's ROE is +0.22%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GMVD's competition here
DXR vs GMVDW Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $10.25, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas GMVDW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GMVDW's competition here
DXR vs AVGR Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, DXR is priced at $10.25, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas AVGR's P/E ratio is -0.05. In terms of profitability, DXR's ROE is +0.22%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, DXR is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check AVGR's competition here
DXR vs GCTK Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, GCTK has a market cap of 416.1K. Regarding current trading prices, DXR is priced at $10.25, while GCTK trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas GCTK's P/E ratio is -0.02. In terms of profitability, DXR's ROE is +0.22%, compared to GCTK's ROE of -3.93%. Regarding short-term risk, DXR is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GCTK's competition here
DXR vs LUCYW Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, LUCYW has a market cap of 320.5K. Regarding current trading prices, DXR is priced at $10.25, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas LUCYW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to LUCYW's ROE of -0.00%. Regarding short-term risk, DXR is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check LUCYW's competition here
DXR vs WOK Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, WOK has a market cap of 6.8K. Regarding current trading prices, DXR is priced at $10.25, while WOK trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas WOK's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to WOK's ROE of -0.07%. Regarding short-term risk, DXR is more volatile compared to WOK. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check WOK's competition here
DXR vs ARTC Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, ARTC has a market cap of 0. Regarding current trading prices, DXR is priced at $10.25, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas ARTC's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to ARTC's ROE of N/A. Regarding short-term risk, DXR is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ARTC's competition here
DXR vs ATRS Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, DXR is priced at $10.25, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas ATRS's P/E ratio is 14.95. In terms of profitability, DXR's ROE is +0.22%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, DXR is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ATRS's competition here
DXR vs IVTY Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, DXR is priced at $10.25, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas IVTY's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, DXR is more volatile compared to IVTY. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check IVTY's competition here
DXR vs IIN Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, IIN has a market cap of 0. Regarding current trading prices, DXR is priced at $10.25, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas IIN's P/E ratio is 226.45. In terms of profitability, DXR's ROE is +0.22%, compared to IIN's ROE of -0.00%. Regarding short-term risk, DXR is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check IIN's competition here
DXR vs HRC Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, HRC has a market cap of 0. Regarding current trading prices, DXR is priced at $10.25, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas HRC's P/E ratio is 41.92. In terms of profitability, DXR's ROE is +0.22%, compared to HRC's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check HRC's competition here
DXR vs ALOG Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, DXR is priced at $10.25, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas ALOG's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, DXR is more volatile compared to ALOG. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ALOG's competition here
DXR vs APR Comparison April 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51.7M. In comparison, APR has a market cap of 0. Regarding current trading prices, DXR is priced at $10.25, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.26, whereas APR's P/E ratio is 22.59. In terms of profitability, DXR's ROE is +0.22%, compared to APR's ROE of +9.81%. Regarding short-term risk, DXR is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check APR's competition here